Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 9,801–9,900 of 10,906
Adult-Onset Still’s Disease after COVID-19 Vaccination: A Case Report and Review
Park, J. W., & Lee, S. W. (2023) · Soonchunhyang Medical Science · doi:10.15746/sms.23.002
The Perception of the Effectiveness of Vaccines between Myth and Reality
Jacomuzzi, A. C. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1003606
Mama roja y vacuna contra la covid-19: ¿posible mastitis? Reporte de un caso
Pérez, R. F., López, P. D., & Lucena, M. A. (2021) · Revista de Senología y Patología Mamaria · doi:10.1016/j.senol.2021.12.011
Şahinci, M. N., Döşkaya, M., Karakavuk, M., Kaplan, S., Mutlu, G., Perçin, T. G., Alak, S. E., Günay-Esiyok, Ö., Gül, A., Döşkaya, A. D., et al. (2025) · Gene · doi:10.1016/j.gene.2025.149965 · Cited by 1
Ilkov, O., Kolesnyk, P., Русановська, О., Mykyta, T., Sabov, O., & Kaliy, V. V. (2022) · Family Medicine · doi:10.30841/2307-5112.1-2.2022.260498 · Cited by 1
Yang, J. E., Fan, H., Yang, A., Wang, W., Wan, X. H., Lin, F., Yang, D., Wu, J., Wang, K., Li, W., et al. (2024) · Vaccines · doi:10.3390/vaccines12070742
Minimax-Regret Sample Selection in Randomized Experiments
Hu, Y., Zhu, H., Brunskill, E., & Wager, S. (2024) · ACM Conference on Economics and Computation (EC) · doi:10.1145/3670865.3673458 · Cited by 11
Majumder, N., & Arefin, M. R. (2026) · Royal Society Open Science · doi:10.1098/rsos.252509
Minhas, M. K., Kumar, A., & Arya, V. (2025) · Medicinal Plants - International Journal of Phytomedicines and Related Industries · doi:10.5958/0975-6892.2025.00044.x
Korves, C., Kulldorff, M., Balajee, A., Smith, J., Zwain, G., Graham, D. J., Whitaker, H., & Izurieta, H. S. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127658 · Cited by 1
Merling, M., Williams, A., Mahfooz, N. S., Ruane-Foster, M., Smith, J., Jahnes, J., Ayers, L., Bazan, J., Norris, A., Turner, A., et al. (2023) · medRxiv · doi:10.1101/2023.01.30.23285195
Robust models of disease heterogeneity and control, with application to the SARS-CoV-2 epidemic
Johnson, K. D., Grass, A., Toneian, D., Beiglböck, M., & Polechová, J. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000412
A Systematic Review - Adverse Effect of Covid-19 Vaccine
Kumar, A., Singh, A., & Gupta, B. K. (2025) · Asian Journal of Research in Chemistry · doi:10.52711/0974-4150.2025.00031
Mannose-appended aminated polyrotaxane for the antigen delivery to antigen-presenting cells
Katanosaka, R., Obata, A., Taharabaru, T., et al. (2026) · Carbohydrate Polymer Technologies and Applications · doi:10.1016/j.carpta.2026.101236
Nagy, H., Hameed, M., Khan, F., Co, E. L., & Rauf, U. (2023) · Avicenna Journal of Medicine · doi:10.1055/s-0042-1760338
Lu, X., Hayashi, H., Ishikawa, E., Takeuchi, Y., Dychiao, J. V. T., Hironori Nakagami, A., & Yamasaki, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.06.543529
Rich dynamics and data analysis of immune decline against SARS-CoV-2
Wang, Z., Jing, S., Xiang, H., et al. (2026) · Advances in Continuous and Discrete Models · doi:10.1186/s13662-026-04069-0
Zhou, J., Li, T., Zhang, W., Qiao, P., Zhang, H., Ding, Z., Lu, Y., Yu, J., Ding, J., Chen, H., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c04529 · Cited by 1
Efficacy of Vaccines Before and During Fourth Wave of COVID-19 in Pakistan - A Comparative Study
Waseem, H., Niazi, A., Khaliq, S. S., Khaliq, N., Khadija, S., & Mufti, M. (2022) · Saudi Journal of Pathology and Microbiology · doi:10.36348/sjpm.2022.v07i09.001
RNA therapeutics and their delivery methods: a paradigm for haemophilia management
Zangi, A. R., Amiri, A., Eskandari, F., Pazooki, P., Heidari, H. R., Hamishehkar, H., & Javadzadeh, Y. (2026) · Journal of drug targeting · doi:10.1080/1061186x.2026.2638330
“…than DNA for therapeutic objectives like protein replacement therapy [59]. to date, mRNA drugs have been developed for the cOviD-19 vaccine [60,61], mAb production [62], the vaccine against infectious disorders, expression of viral antigen in the dendritic cell [63], and protein replacement…”
新型コロナウイルス(COVID-19)ワクチンの供給:世界的危機へのグローバルなアプローチ
OECD (2021) · Singata korona wairusu (Covid-19) he no OECD seisaku tai'ō · doi:10.1787/00fc8ca0-ja
New drug: Elasomeran for prevention of COVID-19
(2021) · Australian Prescriber · doi:10.18773/austprescr.2021.048
Nucleic Acid-Based Systems for Regenerative Medicine
Martín, L., & Grzela, D. P. (2025) · Springer eBooks · doi:10.1007/978-3-031-87744-5_8 · Cited by 1
Pulmonary Delivery of Self-Amplifying RNA: Balancing Inflammation and Durable Transgene Expression
Sun, Q., Cui, X., Li, H., Vervaeke, P., Lienenklaus, S., Gillon, O., Sutter, E. D., Helsmoortel, C., Devriendt, B., Snoeck, J., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c00709
“4,5 10 − 18 The advantage of saRNA vaccines over mRNA vaccines is that they can be used at lower doses and induce a longer-lasting immune response.”
Ali, M., Brady, M., Campbell, P., Rooney, S., Williams, L. J., Paul, L., Mason, H., Manoukian, S., Chung, C. S., Barber, M., et al. (2026) · Health and Social Care Delivery Research · doi:10.3310/gjma0602 · Cited by 1
RNA-Based Molecular Applications as Tool Compounds in Diagnostic and Clinical Settings
Singh, S., Gupta, K., Mishra, S., & Sharma, N. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-3456-9_8
Glenn, D. A., Hu, Y., Free, M. E., Premkumar, L., Narowski, T. M., Coleman, C., Elmore, S., Collie, M. M., Culton, D. A., Orzechowski, N. M., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1813924 · Cited by 1
Editorial: Cardiovascular complications of COVID-19
Marian, A. J. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000846
Sieber‐Schäfer, F., Hagedorn, L., Reger, L., Möbius, K., Winkeljann, B., & Merkel, O. M. (2026) · Nano Letters · doi:10.1021/acs.nanolett.6c00782 · Cited by 5
Vaccination as a Strategy for Cardiovascular Prevention: Closing a Gap in Clinical Practice
de Santiago, E. G., & García‐Lledó, A. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm54010
Design Strategies and Recent Advances in Self-Immolative Lipid Nanoparticles for mRNA Delivery
王, 卓. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1662330
Fan, C., Cohen, A. A., Dam, K.-M. A., Rorick, A. V., Fils, A.-C. I. P., Yang, Z., Gnanapragasam, P. N. P., Segovia, L. N., Huey‐Tubman, K. E., Moon, W. J., et al. (2025) · eLife · doi:10.7554/elife.108959 · Cited by 1
“Initial two-shot COVID-19 mRNA vaccination series became available in December 2020 after clinical studies demonstrated protection from severe disease after SARS- CoV-2 infection ( Polack et al., 2020 ; Baden et al., 2021 ).”
Sun, Y., Khimani, A. H., Tong, Y., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.25.586602
COVID-19 Vaccination Issues in Solid Organ Transplant Recipients
Parabina, E. V., Konstantinov, D. Y., Kaabak, M. M., Rappoport, N. N., Pushkin, S. Y., Selyutin, A. A., Navasardyan, А. S., Владиславовна, М. У., Alexandrova, V. E., & Yaremin, B. I. (2021) · Bulletin of the Medical Institute REAVIZ (REHABILITATION DOCTOR AND HEALTH) · doi:10.20340/vmi-rvz.2021.4.covid.2
Peiter, C., Sala, E., Palma, G. D., Zunarelli, C., Hanson, M. B., Abedini, M., Tacconelli, E., Boffetta, P., & Hasenauer, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.11.731600
“Vaccines were rapidly developed and deployed at unprecedented scale [3,4], and proved highly effective in reducing severe COVID-19 and COVID-19–related mortality [5,6].”
Nair, A., & Kis, Z. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.109034
Numakura, K., Miyamoto, S., Sataka, A., Takeyama, H., & Suzuki, T. (2026) · Communications Health · doi:10.1038/s44528-026-00021-6
Bertoche, L. R., Rodrigues, W. M. R., de Sousa, C. V. A., et al. (2025) · Radiologia Brasileira · doi:10.1590/0100-3984.2025.0004
Ryu, H. E., Yoon, J., Choi, J., Heo, S., Hong, K., & Jung, D. (2024) · Vaccines · doi:10.3390/vaccines12060626 · Cited by 1
Liver injury after COVID-19 vaccination: Current status and future perspectives
Sato, K. (2026) · World Journal of Hepatology · doi:10.4254/wjh.v18.i5.116542
A predictive model for rapid assessment of protective efficacy against emerging SARS-CoV-2 variants
Jin, L., Jia, S., Shao, C., Shen, R., Jin, P., & Li, J. (2026) · Infectious Disease Modelling · doi:10.1016/j.idm.2026.03.003 · Cited by 1
“…et al., 2021; Zhang et al., 2021), as well as 9 studies reporting vaccine efficacy or effectiveness against symptomatic SARS-CoV-2 infection (Baden et al., 2021; Jara et al., 2022; Logunov et al., 2021; Lumley et al., 2021; Novavax, 2021; Pearson, Magalhaes, & Deng, 2021; Polack et al.,…”
Mostafa, H. H., & Pinsky, B. A. (2023) · Wiley eBooks · doi:10.1002/9781683674849.mcm0093
Шелковникова, Т. А., Maksimova, A. S., Ryumshina, N. I., et al. (2022) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2022-491
Reinfection, recontamination and revaccination for SARS-CoV-2
Kullmann, T., & Drozgyik, A. (2022) · World Journal of Methodology · doi:10.5662/wjm.v12.i4.258 · Cited by 1
Editorial: COVID-19 immunology and organ transplantation
Bery, A. I., Kulkarni, H. S., & Kreisel, D. (2021) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000862 · Cited by 1
Sharma, R., & Anand, A. (2021) · medRxiv · doi:10.1101/2021.06.05.21258394
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0002
Zhang, J. (2023) · Springer series in biophysics · doi:10.1007/978-3-031-36773-1_27
Changes Over Time in COVID-19 Vaccination Inequalities in Eight Large U.S. CitiesPreprint
Gaddis, S. M., Carey, C. M., & DiRago, N. V. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.3975859
From COVID to cancer: Why Canada’s RNA vaccine leadership matters more than ever
Blakney, A. K., & Cullis, P. R. (2025) · doi:10.64628/aam.pjkdshty6
Strategies for Working With Parents With Vaccination Hesitancy
Kirui, J. C., Newberry, D., & Harsh, K. (2023) · Neonatal Network The Journal of Neonatal Nursing · doi:10.1891/nn-2022-0055 · Cited by 1
POUCHAIN, D., Boussageon, R., & Ferrat, É. (2021) · EXERCER · doi:10.56746/exercer.2021.170.71
Insights from qualitative and bifurcation analysis of COVID-19 vaccination model in Bangladesh
Kuddus, M. A., Mohiuddin, M., Paul, A. K., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312780
Örlős, Z., Miklós, Z., & Horváth, I. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.32994
SARS-CoV-2 mRNA Vaccination Induces Reduced T-Cell Apoptosis in Patients with Solid Tumors
Belda-Marco, A., Serrano-García, L., Moret, A., Fresneda‐Portillo, C., Domínguez-Márquez, M. V., Comes-Raga, A., Jávega, B., O’Connor, J., Andreu‐Ballester, J. C., Llombart‐Cussac, A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146173
“…and mRNA-1273 (Moderna) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) demonstrated the remarkable efficacy of this platform, achieving high protection rates against symptomatic COVID-19 in the general population and becoming a cornerstone of pandemic control [4,5].”
“Fair Innings,” Women, and Longevity Science
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0008
Lipid Nanoparticle-Delivered mRNA Therapy Corrects Neonatal Murine MPS I-H
Fu, J., Luo, M., Jin, X., Su, J., Song, L., Qiuxia, X., Liu, F., Wu, X., Luo, M., Ye, Q., et al. (2026) · Human Gene Therapy · doi:10.1177/10430342251412392
COVID-19 Pandemic and Vaccination
Oster, Y. (2023) · Reproductive medicine for clinicians · doi:10.1007/978-3-031-24903-7_2
Sen, S., Prusty, P. K., Rawat, A., Gurajala, S., Jyothikiran, H., & Rathi, R. K. (2024) · Multidisciplinary Reviews · doi:10.31893/multirev.2023ss003
COVID-19 and patients on renal replacement therapy: Perspective from the State of Qatar
Hamad, A., Alkadi, M. M., & Al-Malki, H. A. (2024) · Qatar medical journal · doi:10.5339/qmj.2024.1
COVID-19 vaccines and their impact: An overview
Khong, K.-W., & Hung, I. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95646-8.00002-0
MHC one–two punch knocks out cancer
Ghorbani, A., & Yewdell, J. W. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20252203
Liu, Y., Zhou, J., Gong, Z., Feng, Y., Li, X., Shang, Q., Wu, Y., & Yang, Y. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101612 · Cited by 2
Kurniawan, A., Koesnoe, S., Yunihastuti, E., et al. (2024) · Medicines · doi:10.3390/medicines11060012
Pasricha, P. K., & Upadhayaya, A. K. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.21.470882
Bell’s Palsy Following SARS-CoV-2 Vaccines: A Systematic Review and Meta-AnalysisPreprint
Rafati, A., Pasebani, Y., Jameie, M., Yang, Y., Jameie, M., Ilkhani, S., Amanollahi, M., Sakhaei, D., Rahimlou, M., & Kheradmand, A. (2022) · medRxiv · doi:10.1101/2022.10.26.22281537
Timing of COVID19 vaccination drives menstrual cycle changesPreprint
Edelman, A. B., Boniface, E. R., Male, V. H., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3171222/v1
Takatori, M., Nemoto, A., Hirotsu, Y., Mikawa, T., Honda, R., Ono, M., Endo, A., Shibamori, K., Shiozawa, R., Maejima, M., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.01288-25
Vaccination des seniors : un impératif de santé publique au défi de l’immunosénescence
Lelièvre, P. J.-D. (2026) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(26)76564-3
Schoepf, I. C., Riebensahm, C., Becchetti, C., Blaser, V., Unternährer, C. V., Banz, V. M., Hirzel, C., Suter‐Riniker, F., & Berzigotti, A. (2023) · Swiss Medical Weekly · doi:10.57187/smw.2023.40118
Coronavirus Disease 2019 Vaccines and Pregnancy: Present and Future
Pae, J., & Ko, H. S. (2021) · Perinatology · doi:10.14734/pn.2021.32.3.111
Reflections on Pending Technical and Legal Issues in the R&D of COVID-19 Medical Products
LI, N., DONG, Y., & YU, X. (2025) · Biotechnology Law Report · doi:10.1089/blr.2025.80807.nl
INCIDÊNCIA DA COVID-19 NO RIO GRANDE DO NORTE E ESTRATÉGIAS DE CONTROLE DA PANDEMIA
Lucena, D. D. S., Nascimento, D. P. C. D., Leite, I. F., et al. (2024) · Revista de Ciências da Saúde Nova Esperança · doi:10.17695/rcsne.vol22.n2.p174-182
Arral, M. L., Chaudhary, N., Fein, K. C., Newby, A. N., Yerneni, S. S., Melamed, J. R., LoPresti, S. T., Petersen, D. M. S., & Whitehead, K. A. (2026) · Drug Delivery and Translational Research · doi:10.21203/rs.3.rs-9763025/v1 · Cited by 1
Zur Konkurrenz der Impfstoffe gegen COVID-19: Aufklärung und Auswahl
Hart, D. (2021) · Medizinrecht · doi:10.1007/s00350-021-5845-7
Safety and efficiency of COVID-19 vaccine in North Africa
Chelly, S., Jaziri, S., Ammar, A., Ezzi, O., douss, N., Saffar, S., Tritar, M., Njah, M., & Mahjoub, M. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2306703 · Cited by 1
Condé, M. L., Barry, S. D., Touré, M. L., Diallo, M. T., Doumbouya, M. S., Doré, M., Camara, I., Laila, T., Diawara, K., Camara, N., et al. (2022) · OALib · doi:10.4236/oalib.1109332
COVID-19 vaccines: A comprehensive review of safety and efficacy
Yan, Z., Yang, M., & Lai, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19170-1.00028-0
Safety and Side Effects of COVID-19 Vaccines
Mielniczek, K. (2021) · Journal of Education Health and Sport · doi:10.12775/jehs.2021.11.09.039
Akhrass, F. A., Reynolds, N., Akhrass, C. A., Dawahare, J. H., Raj, R., Green, G., & Hom, R. C. (2021) · Research Square · doi:10.21203/rs.3.rs-612401/v1 · Cited by 1
An Agent-Based Modeling Framework to Analyze Spread of Infection in a Network of Nursing HomesPreprint
Corkran, K., Gómez-Vázquez, J. P., Arjmand, A., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4774397
Healy, C. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-54841-0.00006-8
Covid-19 vaccination acceptance among visitors of Erbil primary health care centers
Sulaiman, K. H. (2024) · Diyala Journal of Medicine · doi:10.26505/djm.v26i1.1085
Nanotechnology in COVID-19 Vaccines
Jain, A., & Sharma, S. (2022) · doi:10.2991/978-94-6463-020-6_3 · Cited by 1
Regan, T., Wills, W., Barbera, A., Reyes, P. E., Jacklin, K., Crowder, D. L., Henderson, K., Montes, B., & Bugajski, A. (2023) · Cureus · doi:10.7759/cureus.51229
Singaravelu, S., Balu, R., Senthilkumar, C., & Jayaprakash, J. (2026) · Frontiers in Biomaterials Science · doi:10.3389/fbiom.2026.1912922
COVID-19 and Solid Organ Transplantation: What We Learned and Where We are Going
Huang, J., & Pouch, S. M. (2026) · Current Infectious Disease Reports · doi:10.1007/s11908-026-00881-7
Alves, K., Kotloff, K. L., McClelland, R. S., Hammershaimb, E. A., Kouassi, A., Plested, J. S., Kalkeri, R., Zhu, M., Cloney-Clark, S., Cai, Z., et al. (2025) · medRxiv · doi:10.1101/2025.04.09.25325550
Self-citationNaturopathic Medicine on the Frontline of the COVID-19 Pandemic
Halldorson, C. (2021) · CAND Journal · doi:10.54434/candj.94
COVID-19-Impfung: mRNA-1273 effektiv und sicher
(2021) · Pneumologie · doi:10.1055/a-1481-3434
Bitler, J. (2022) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v25i3.7016
Odhar, H. A. (2023) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/q4u5d
Nebane, N. M., Reece, A., Rasmussen, L. A., et al. (2025) · SLAS DISCOVERY · doi:10.1016/j.slasd.2025.100246
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.